Product custom-nanocomposites-lipid-nanoparticle-composite-materials

Home > products > custom-nanocomposites> lipid-nanoparticle-composite-materials

Catalog	name	Description	price
R-R-5729	PEGylated DOTA Liposomes for Remote Loading Radioactive Divalent	CDOTA encapsulated liposomes are used for remote loading of radioactive divalent ions such as radioactive copper into the liposomes. Cationic ions will not pass through the membrane if there is no pH gradient. Divalent ion will cross the liposome membrane only when there is a flux of proton across of the lipid membrane. Due to the difference in the pH inside and outside of the liposomes, there will be a constant flux of proton from inside of the liposomes to outside of the liposomes. Due to this flux, divalent cations move in the opposite direction from outside to inside of liposomes. Liposomes are thermodynamically stable structures and not very permeable to divalent cations after they are formed. If there is no pH gradient, divalent cations cannot move from outside to inside of the liposomes, where they will remain outside and won’t cross the membrane. The driving force for remote loading in proton gradient. The radioactive divalent copper is externally added to the liposomes. The divalent ion passes the membrane using pH gradient method and chelates DOTA.	price>
R-R-5731	(PEGylated)Doxosome-Doxorubicin Liposomes	PEGylated Doxorubicin Liposomes are a type of non surface reactive doxorubicin liposome.The formulation of this doxorubicin liposome is PEGylated and is only used for research purposes and laboratory animal injection. The doxorubicin drug has been remotely loaded into liposomes via ammonium sulfate gradient. Surface reactive doxorubicin liposomes suitable for coupling various antibodies, proteins, peptides, and ligands are also available.	price>
R-R-5732	(PEGylated) Doxosome Control-Doxorubicin Liposomes	(PEGylated) Doxosome Control-Doxorubicin Liposomes is a control formulation of PEGylated Doxorubicin liposomes. This formulation is similar in size and lipid composition to PEGylated Doxorubicin liposomes but does not contain the Doxorubicin drug. This formulation is for research purposes and injection into laboratory animals only.	price>
R-R-5733	Doxorubicin liposomes for post-insertion (non-PEGylated)	Doxorubicin is a widely used chemotherapeutic agent that has been formulated into liposomal drug delivery systems to enhance its therapeutic efficacy while reducing systemic toxicity. Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate hydrophilic and hydrophobic drugs. Non-PEGylated doxorubicin liposomes represent a specific formulation that does not utilize polyethylene glycol (PEG) to modify the liposomal surface.	price>
R-R-5734	Preformed Doxorubicin Liposomes(HSPC :Cholesterol)(60:40 molar ratio)	Preformed doxorubicin liposomes are an advanced formulation designed to deliver the chemotherapeutic agent doxorubicin in a manner that enhances its efficacy and reduces systemic toxicity. The specific liposomal formulation described comprises HSPC (hydrogenated soy phosphatidylcholine) and cholesterol in a 60:40 molar ratio, which plays a critical role in defining the physiochemical properties and performance of the liposomes.	price>
R-R-5735	Surface Reactive Doxorubicin Liposomes-Cyanur (PEGylated)	Surface reactive doxorubicin liposomes with cyanur and PEGylation represent a significant advancement in the field of targeted cancer therapy. This formulation aims to enhance the therapeutic properties of doxorubicin while minimizing toxicity, thus contributing to improved treatment outcomes for cancer patients. Ongoing research in this area continues to refine liposomal formulations, optimize targeting capabilities, and evaluate their effectiveness in clinical settings.	price>
R-M1-cs8797	ROS responsive liposomes loaded with CE6+ML385+L-arginine	By combining these three components (CE6, ML385, and L-arginine) within ROS responsive liposomes, it is possible to create a targeted drug delivery system that responds to specific oxidative conditions found in the body. The release of the cargo can be triggered by ROS, leading to local therapeutic effects.	price>
R-M1-cs8798	ROS responsive liposomes loaded with CE6+ML385	The combination of CE6 and ML385 in ROS responsive liposomes can be particularly useful in targeting and treating diseases or conditions characterized by high ROS levels, such as certain cancers, inflammatory disorders, and oxidative stress-related diseases.	price>
R-M2-9508	PLGA-imatinib nanoparticles	PLGA-imatinib nanoparticles can be used as a formulation for treating CML and GISTs, improving drug efficacy and reducing side effects associated with systemic administration.They can potentially be used to co-deliver other chemotherapeutics or radiosensitizers, allowing for synergistic effects in cancer treatment.	price>
R-M1-8676	Blank Lipid nanoparticles-GIn(100nm)	Blank lipome nanoparticles-GIn/Blank liposome nanoparticles-GIn(100nm) can be used for drug loading, drug delivery and targeted cell research.	price>

...